when is retatrutide expected to be available Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide vs Tirzepatide vs Semaglutide

Endometriomas These cysts are a result of the tissue that normally grows inside the uterus to develop on the outside of the uterus which then attaches to the ovaries

Usually manageable and improves as the body adapts

And while results can be impressive in the short term, the long-term picture is more complex: in one clinical study, participants regained two-thirds of their lost weight within a year of stopping treatment

Ipamorelin was not among the peptides the committee reconsidered at its July 2026 meeting, so as of August 2026 that 2024 recommendation still stands

Updated guidelines and current treatment recommendations are a solid basis for this opinion

Potential Risks and Considerations Even setting aside regulatory status, any consideration of growth hormone stimulating compounds requires awareness of potential risks that appear in the clinical and safety literature: Water retention and edema Joint pain (arthralgia), which is a known side effect of GH elevation Potential impact on insulin sensitivity GH affects glucose metabolism Theoretical concerns about stimulating GH in individuals with undiagnosed malignancies (GH is a growth factor) Unknown long-term effects from extended use in healthy adults Quality and purity concerns when obtained outside regulated pharmaceutical channels These considerations underscore why any decision regarding peptide therapy must involve a physician who can review individual medical history, contraindications, and current evidence not a wellness clinic, online pharmacy, or influencer recommendation